RESUMO
All wound infection presents risks for the patient, but the risks are multiplied in the presence of a comorbidity such as diabetes, when they can potentially be fatal. Where diabetic foot ulcer (DFU) infection is concerned, early recognition is crucial. Prompt treatment, comprising wound cleansing, debridement of devitalised tissue and use of antimicrobial dressings, can stop locally infected ulcers from deteriorating further.
Assuntos
Anti-Infecciosos/uso terapêutico , Pé Diabético/diagnóstico , Pé Diabético/terapia , Saúde Holística , Guias de Prática Clínica como Assunto , Infecção dos Ferimentos/diagnóstico , Infecção dos Ferimentos/tratamento farmacológico , Adulto , Bandagens , Desbridamento , Diabetes Mellitus/epidemiologia , Pé Diabético/complicações , Diagnóstico Precoce , Humanos , Masculino , Cicatrização , Infecção dos Ferimentos/complicaçõesRESUMO
INTRODUCTION: The vascular impairment of erection has been shown in diabetic patients as well as in patients with Peyronie's disease (PD). However, the impact of both conditions together on vascular impairment has not been well addressed. AIM: The aim of this study was to assess the impact of type 2 diabetes mellitus (DM) and PD solely, and together, on impairment of vascular status of erection in patients with erectile dysfunction (ED). METHODS: Three hundred four male patients with a clinical diagnosis of ED who visited our Andrology clinic and who had DM and/or PD were enrolled in this study. Of the patients, 214, 28, and 62 had DM, PD, and both DM and PD, respectively. Patients were interviewed for ED using the International Index of Erectile Function. All patients were also interviewed for sociodemographic data and medical comorbidities including DM. The diagnosis of PD was based on a palpable penile plaque or acquired penile curvature. Color Doppler ultrasonography was used to evaluate the hemodynamics of erection in all patients. MAIN OUTCOME MEASURES: We assessed the impact of type 2 DM and PD on erectile function (EF) domain and on deterioration of Doppler parameters of erection. RESULTS: Age, obesity, smoking, and medical comorbidities were significantly higher in patients with both DM and PD than in patients with any of the conditions alone. The means of EF domain, Q3, and Q4 were significantly lower in patients with both DM and PD than in patients with any of the conditions alone. Patients with DM only had significantly lower means of EF domain, Q3, and Q4 than patients with PD only. The means of peak systolic velocity and resistive index were significantly lower, and the means of end-diastolic velocity were significantly higher in patients with both DM and PD than in patients with any of the conditions alone. CONCLUSIONS: Type 2 DM and PD solely, and together, negatively affect the vascular status of erection. Type 2 DM demonstrated the principal effect; however, presence of PD has an additive impairment effect on erection and Doppler parameters.
Assuntos
Diabetes Mellitus Tipo 2/epidemiologia , Disfunção Erétil , Induração Peniana , Pênis/irrigação sanguínea , Pênis/fisiopatologia , Adulto , Idoso , Índice de Massa Corporal , Comorbidade , Diabetes Mellitus Tipo 2/diagnóstico , Disfunção Erétil/diagnóstico , Disfunção Erétil/epidemiologia , Disfunção Erétil/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Obesidade/diagnóstico , Obesidade/epidemiologia , Induração Peniana/diagnóstico , Induração Peniana/epidemiologia , Induração Peniana/fisiopatologia , Pênis/diagnóstico por imagem , Prevalência , Estudos Prospectivos , Índice de Gravidade de Doença , Ultrassonografia Doppler em Cores , Adulto JovemRESUMO
AIMS: To describe the characteristics and fasting experience of a subgroup of patients in the VISION study who initiated insulin therapy and chose to fast during Ramadan, and to discuss the VISION Ramadan substudy data in the context of previous Ramadan studies. METHODS: The VISION study was a prospective, non-interventional, observational study of adult patients with Type 2 diabetes mellitus in 6 countries in the Western Pacific, Middle East and North Africa, receiving insulin injection therapy for the first time. In this VISION Ramadan substudy, fasting data was collected during Ramadan 2014 and 2015. RESULTS: Of 1617 patients in the VISION study, data was collected for 357 patients who chose to fast during Ramadan. At baseline, mean HbA1c was 10.1%, duration of diabetes was 8.8â¯years, and mean BMI was 30â¯kg/m2. All patients with non-missing data (nâ¯=â¯169) received advice on fasting during Ramadan. The majority of patients fasted for the full month of Ramadan, and around one-third of patients fasted outside Ramadan. CONCLUSIONS: Here we provide an update on the characteristics and Ramadan experience of patients with Type 2 diabetes mellitus who initiated insulin therapy and chose to fast during Ramadan. There is still a need to explore patient's experience during fasting, and identify and address methods to better help manage those patients.
Assuntos
Diabetes Mellitus Tipo 2/terapia , Jejum/efeitos adversos , Diabetes Mellitus Tipo 2/patologia , Feminino , Humanos , Insulina , Islamismo , Masculino , Pessoa de Meia-Idade , Estudos ProspectivosRESUMO
AIMS: The impact of introducing new classes of glucose-lowering medication (GLM) on diabetes management remains unclear, especially outside North America and Western Europe. Therefore, we aimed to analyse trends in glycaemic control and the usage of new and old GLMs in people with type 2 diabetes from 2006 to 2015. METHODS: Summary data from clinical services from nine countries outside North America and Western Europe were collected and pooled for statistical analysis. Each site summarized individual-level data from out-patient medical records for 2006 and 2015. Data included: demographics; HbA1c and fasting plasma glucose levels; and the proportions of patients taking GLM as monotherapy, combination therapy and/or insulin. RESULTS: Between 2006 and 2015, glycaemic control remained stable, although body mass index and duration of diabetes increased in most sites. The proportion of people on GLM increased, and the therapeutic regimens became more complex. There were increases in the use of insulin and triple therapy in most sites, while monotherapy, particularly in relation to sulphonylureas, decreased. Despite the introduction of new GLMs, such as DPP-4 inhibitors, insulin use increased over time. CONCLUSIONS: There was no clear evidence that the use of new classes of GLMs was associated with improvements in glycaemic control or reduced the reliance on insulin. These findings were consistent across a range of economic and geographic settings.
Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Inibidores da Dipeptidil Peptidase IV/uso terapêutico , Uso de Medicamentos/estatística & dados numéricos , Insulina/uso terapêutico , Compostos de Sulfonilureia/uso terapêutico , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/epidemiologia , Inibidores da Dipeptidil Peptidase IV/administração & dosagem , Gerenciamento Clínico , Europa (Continente) , Humanos , Insulina/administração & dosagem , América do Norte , Compostos de Sulfonilureia/administração & dosagemRESUMO
Ramadan fasting is one of the five pillars of Islam and is compulsory for all healthy Muslims from puberty onwards. Exemptions exist for people with serious medical conditions, including many with diabetes, but a large number will participate, often against medical advice. Ensuring the optimal care of these patients during Ramadan is crucial. The International Diabetes Federation (IDF) and Diabetes and Ramadan (DAR) International Alliance have come together to deliver comprehensive guidelines on this subject. The key areas covered include epidemiology, the physiology of fasting, risk stratification, nutrition advice and medication adjustment. The IDF-DAR Practical Guidelines should enhance knowledge surrounding the issue of diabetes and Ramadan fasting, thereby empowering healthcare professionals to give the most up-to-date advice and the best possible support to their patients during Ramadan.
Assuntos
Aconselhamento/normas , Diabetes Mellitus/terapia , Jejum , Islamismo , Guias de Prática Clínica como Assunto , Adolescente , Adulto , Diabetes Mellitus/tratamento farmacológico , Feminino , Humanos , Educação de Pacientes como Assunto/normas , Gravidez , Gravidez em Diabéticas/terapia , Risco , Adulto JovemRESUMO
The challenge of insulin use during Ramadan could be minimized, if people with diabetes are metabolically stable and are provided with structured education for at least 2-3 months pre-Ramadan. Although, American diabetes association (ADA) recommendations 2010 and South Asian Consensus Guideline 2012 deal with management of diabetes in Ramadan and changes in insulin dosage, no specific guidance on widely prescribed low-ratio premix insulin is currently available. Hence, the working group for insulin therapy in Ramadan, after collective analysis, evaluation, and opinion from clinical practice, have formulated a practical advice to empower physicians with pre-Ramadan preparation, dose adjustment, and treatment algorithm for self-titration of low-ratio premix insulin.
RESUMO
We have reported a case of a 40-year-old male diabetic patient, resident of a rural area, who visited the outpatient clinic of the diabetic center in Alnoor Specialist Hospital, Makkah, Saudi Arabia. He came to seek medical advice for a single wound in the back of the shoulder since 1 month. After examination, a larva was eliminated and sent to laboratory for confirmation. It was confirmed as the third-stage larva of Sarcophaga species after macroscopic and microscopic examination. This is the first case of a patient having diabetic wound myiasis with the larva of Sarcophaga species reported in the Makkah region of Saudi Arabia.
RESUMO
OBJECTIVES: To determine the incidence of hypoglycaemia during Ramadan in Muslim subjects with type 2 diabetes treated with a sulphonylurea. METHODS: In an observational study, eligible subjects were Muslims with type 2 diabetes (age ≥18 years) who were treated with glimepiride, gliclazide, or glibenclamide with or without metformin and who expressed their intention to fast during Ramadan in 2009. Subjects were recruited by clinicians in India, Malaysia, Israel, the United Arab Emirates (UAE), and Saudi Arabia. Each day during Ramadan, patients completed diary cards, which collected information regarding hypoglycaemic symptoms and complications, time from last meal and from last medication, self-monitored blood glucose measurements, and need for assistance. The overall incidence of symptomatic hypoglycaemia recorded during Ramadan was the primary endpoint of interest. RESULTS: Of the enrolled subjects (N = 1397), 1378 returned their diary cards at study end and were included in the analysis. Overall, 89% of subjects who expressed their intention to fast prior to Ramadan reported that they observed the fast during Ramadan. A total of 271 subjects (19.7%) experienced one or more symptomatic hypoglycaemic events during Ramadan, with incidences of 25.6%, 16.8%, and 14.0% observed in subjects treated with glibenclamide, glimepiride, and gliclazide, respectively. By country, the highest incidence of hypoglycaemia was reported by subjects from Israel (40%) followed by those from Malaysia (24%), the UAE (18%), India (13%), and Saudi Arabia (10%). The overall incidence of severe hypoglycaemic events (i.e., events requiring medical or non-medical assistance) was 6.7%, with the highest incidence occurring in the glibenclamide group. LIMITATIONS: This was an observational study and as such subjects were not randomised to treatments. While baseline measures appeared comparable, it is possible that differences in measured and unmeasured patient characteristics (e.g., measures of glycaemic control) could partially explain these results. Lastly, no inferential testing was performed on the comparisons between sulphonylurea types and/or countries. CONCLUSIONS: In this five-country observational study, nearly 20% of sulphonylurea-treated Muslim subjects with type 2 diabetes experienced symptomatic hypoglycaemia while fasting during Ramadan, with variations across sulphonylureas and countries.
Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Jejum , Hipoglicemia/complicações , Hipoglicemiantes/uso terapêutico , Islamismo , Compostos de Sulfonilureia/uso terapêutico , Adulto , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/complicações , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
BACKGROUND: Idiopathic thrombocytopenic purpura (ITP) in adults has a chronic course and may necessitate splenectomy. The current study was undertaken to study the systemic thromboembolic complications of laparoscopic splenectomy (LS) versus open splenectomy (OS) in patients with ITP at two large referral hospitals. PATIENTS AND METHODS: We conducted a retrospective analysis of 49 patients who underwent splenectomy (21 LS and 28 OS) for primary/relapsing refractory ITP between June 1995 and November 2004. Clinically and/or radiologically confirmed deep venous thrombosis (DVT) and/or pulmonary embolism (PE) were assessed within 2 weeks before and after splenectomy. None had prophylactic anticoagulants immediately after surgery. Follow up of those who developed complications continued for at least 2 additional years to assess for contributing factors that may have been masked at the time of occurrence. RESULTS: Two (9.5%) LS group had acute PE within 5 days of LS and their platelet count reached 500A103/I(1/4)L within 4 days and 1000A103/I(1/4)L within 7 days after surgery. Three conversions to OS occurred; none had VTE. DVT occurred in 3 patients (10.7%) in the OS group; none were life threatening. There were no deaths. CONCLUSION: Life-threatening venous thromboembolic events are serious complications after LS and OS for ITP patients if prophylactic anticoagulants are not administered. Patients at risk are those who both have an exponential rise of the platelet count, although factors other than the platelet count may be contributing in OS. Postsplenectomy, ITP should be considered as a thrombophilic condition and studies of additional measures to prevent such events are warranted.
Assuntos
Anticoagulantes , Laparoscopia , Complicações Pós-Operatórias/etiologia , Embolia Pulmonar/etiologia , Púrpura Trombocitopênica Idiopática/cirurgia , Esplenectomia , Trombose Venosa/etiologia , Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/prevenção & controle , Embolia Pulmonar/prevenção & controle , Estudos Retrospectivos , Trombose Venosa/prevenção & controleRESUMO
OBJECTIVES: To assess the impact of diabetes mellitus (DM) control on androgen pattern in men with type 2 DM-associated erectile dysfunction (ED). METHODS: This is a prospective office-based study. A total of 159 ED male patients with DM were enrolled in this study. Erectile function was assessed using the international index of erectile function (IIEF). Diabetes control was instituted using lifestyle modification in addition to hypoglycemic agents and/or insulin therapy. Regular follow-up visits were scheduled every 4 weeks to adjust the anti-DM treatment according to patients' response and tolerance. At baseline, 3- and 6-month visits, patients were assessed for control of DM, ED severity, and total testosterone (T), dehydroepiandrosterone sulfate (DHEA-S), and insulin assessment. RESULTS: Of all patients, 25.8%, 6.3%, and 30.2% had low total T, low DHEA-S, and hyperinsulinemia, respectively, at baseline visit. There were significant increases in the mean total T levels (4.2 +/- 1.9 vs 4.7 +/- 2.1 and 5.3 +/- 2.2) and significant decreases in insulin level (23.7 +/- 17.4 vs 22.8 +/- 15.3 and 17.8 +/- 13.9) at 3- and 6-month visits, respectively. There were significant associations between good control of DM or decreased fasting blood sugar and normal levels of total T at 3- and 6-month visits. The prevalence of patients with normal testosterone and severe ED was significantly increased at 3- and 6-month visits. CONCLUSIONS: The present study clearly demonstrated that there were significant associations between control of DM and normal total T levels at 3- and 6-month follow-up visits.